Mike Crapo bought Pharma Partners, LLC Company: Pharma Partners, LLC (Englewood, CO) Description: The LLC funds research and clinical trials on a new class of drugs, metalloporphyrins. The lead drugs are BMX-010 and BMX-001. (--)
Mike Crapo (R-ID), a U.S. Senator, has disclosed 1 trade in Pharma Partners, LLC Company: Pharma Partners, LLC (Englewood, CO) Description: The LLC funds research and clinical trials on a new class of drugs, metalloporphyrins. The lead drugs are BMX-010 and BMX-001. (--) since 2017, a single purchase, worth an estimated $75K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a purchase: Mike Crapo bought $50,001 - $100,000 of Pharma Partners, LLC Company: Pharma Partners, LLC (Englewood, CO) Description: The LLC funds research and clinical trials on a new class of drugs, metalloporphyrins. The lead drugs are BMX-010 and BMX-001. (--) on November 27, 2017. Since that trade, -- is up +0.00% against the S&P 500 up +229.69%, an outperformance of -229.69%.
Data updated
Mike Crapo's -- trades vs the price
-- is up +0.00% since Mike Crapo bought on November 27, 2017, versus +229.69% for the S&P 500.
Performance since this trade
All Mike Crapo -- trades
Mike Crapo & -- trading FAQ
Is it legal for Mike Crapo to trade Pharma Partners, LLC Company: Pharma Partners, LLC (Englewood, CO) Description: The LLC funds research and clinical trials on a new class of drugs, metalloporphyrins. The lead drugs are BMX-010 and BMX-001. (--) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Pharma Partners, LLC Company: Pharma Partners, LLC (Englewood, CO) Description: The LLC funds research and clinical trials on a new class of drugs, metalloporphyrins. The lead drugs are BMX-010 and BMX-001. (--), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. BullishWhales tracks those disclosures; this page does not imply the trade was improper.
When did Mike Crapo buy --?
Mike Crapo disclosed a purchase of $50,001 - $100,000 of Pharma Partners, LLC Company: Pharma Partners, LLC (Englewood, CO) Description: The LLC funds research and clinical trials on a new class of drugs, metalloporphyrins. The lead drugs are BMX-010 and BMX-001. (--) on November 27, 2017, according to public STOCK Act filings.
How has -- performed since Mike Crapo's trade?
Since Mike Crapo bought -- on November 27, 2017, the stock is up +0.00%, versus +229.69% for the S&P 500 over the same period, an outperformance of -229.69%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional -- trades?
BullishWhales tracks every disclosed congressional trade in Pharma Partners, LLC Company: Pharma Partners, LLC (Englewood, CO) Description: The LLC funds research and clinical trials on a new class of drugs, metalloporphyrins. The lead drugs are BMX-010 and BMX-001. (--) on the Pharma Partners, LLC Company: Pharma Partners, LLC (Englewood, CO) Description: The LLC funds research and clinical trials on a new class of drugs, metalloporphyrins. The lead drugs are BMX-010 and BMX-001. congressional trading page, which aggregates filings across all members of Congress.
Mike Crapo's -- tradesAll congressional filings for Pharma Partners, LLC Company: Pharma Partners, LLC (Englewood, CO) Description: The LLC funds research and clinical trials on a new class of drugs, metalloporphyrins. The lead drugs are BMX-010 and BMX-001.Mike Crapo's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.